Retatrutide is an investigational peptide that simultaneously activates three key metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique triple agonist mechanism makes it particularly effective for metabolic research applications.
Clinical studies have demonstrated Retatrutide's superior weight loss potential compared to single or dual agonist peptides. In trials, Retatrutide showed a 25% reduction in body weight within 48 weeks, significantly outperforming other peptides in its class.
Our Retatrutide peptide powder meets the highest purity standards with HPLC-verified purity of 99.88% minimum. The lyophilized white powder is supplied in research-grade packaging with proper storage recommendations.
- Metabolic syndrome research
- Obesity mechanism studies
- Glucose metabolism investigations
- Weight management research
1. Semaglutide (GLP-1 agonist): 6-12% weight reduction in 28 weeks
2. Tirzepatide (GLP-1/GIP agonist): 15-20% weight reduction in 72 weeks
3. Retatrutide (GLP-1/GIP/Glucagon agonist): 25% weight reduction in 48 weeks
For optimal stability, store at 2-8°C protected from light. The product has a shelf life of 24 months when properly stored.